A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms

Andrea Frilling; Ashley K. Clift; Adam E. Frampton; Jamshed Bomanji; Daniel Kaemmerer; Adil Al-Nahhas; Ali Alsafi; Mark Kidd; Irvin M. Modlin; Dieter Hoersch; Richard P. Baum

doi:10.7150/ijms.51740

Back

A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms

Journal article

Open access

A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms

Andrea Frilling, Ashley K. Clift, Adam E. Frampton, Jamshed Bomanji, Daniel Kaemmerer, Adil Al-Nahhas, Ali Alsafi, Mark Kidd, Irvin M. Modlin, Dieter Hoersch, …

International journal of medical sciences, Vol.18(10), pp.2166-2175

01/01/2021

DOI: https://doi.org/10.7150/ijms.51740

PMID: 33859524

Abstract

Research Paper

Rationale: Neuroendocrine neoplasia (NEN) of small bowel (SBNEN) frequently present with metastatic disease. Theranostics (molecular imaging followed by targeting therapy) allow for personalised medicine. Liquid biopsies enable precise identification of residual disease and real-time monitoring of therapeutic response. Our aim was to determine the clinical utility of a combination of surgery, theranostics, and a multigene blood measurement in metastasised SBNEN. Methods: Inclusion criteria were SBNEN, G1/G2 NEN, initial tumour diagnosis, stage IV NEN, positivity on 68 Ga somatostatin analogue PET/CT, eligible for surgery, and 177 Lu peptide receptor radionuclide therapy (PRRT). Blood samples for NETest were collected longitudinally. Progression-free survival (PFS) and overall survival (OS) were calculated. NETest results were assessed prior to surgery and during clinical follow-up. Results: A surgical cohort of 39 SBNEN patients met eligibility criteria. Thirty-two patients underwent ileal resection and 7 right hemicolectomy. The mean number of 177 Lu PRRT cycles was 4. Mortality was nil. Surgical morbidity was 10.3%. Transient grade 1/2 toxicity occurred in 41% (PRRT). NETest scores (n=9 patients) decreased in 100% following treatment and correlated with diminished tumour volume and disease stabilization following surgery and PRRT. Median follow-up: 78 months. Median PFS and OS: 42.7 and 110 months, respectively. Progression-free survival at 1-, 3-, and 5-years was 79.4%, 57.1% and 40.5%, respectively. Overall survival at 1-, 3-, and 5-years was 97.4%, 97.4%, and 94.1%, respectively. Conclusions: Surgery combined with 177 Lu PRRT is safe and provides favourable PFS and OS in selected patients with advanced SBNEN. Liquid biopsy (NETest) has the potential to accurately delineate disease status.

Files and links (1)

url

https://doi.org/10.7150/ijms.51740View

Published (Version of record) Open

Metrics

Details

Title: A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms
Creators: Andrea Frilling - Department of Surgery and Cancer, Imperial College London, London, UK. Department of Nuclear Medicine, University College London Hospitals, London, UK. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. Department of Imaging and Nuclear Medicine, Imperial College London, London, UK. WREN Laboratories, Branford, USA. Gastroenterological and Endoscopic Surgery, Yale University School of Medicine, New Haven, USA. Department of Gastroenterology/Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany. CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany
Ashley K. Clift - UCL Australia
Adam E. Frampton - UCL Australia
Jamshed Bomanji - Department of Surgery and Cancer, Imperial College London, London, UK. Department of Nuclear Medicine, University College London Hospitals, London, UK. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. Department of Imaging and Nuclear Medicine, Imperial College London, London, UK. WREN Laboratories, Branford, USA. Gastroenterological and Endoscopic Surgery, Yale University School of Medicine, New Haven, USA. Department of Gastroenterology/Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany. CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany
Daniel Kaemmerer - Department of Surgery and Cancer, Imperial College London, London, UK. Department of Nuclear Medicine, University College London Hospitals, London, UK. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. Department of Imaging and Nuclear Medicine, Imperial College London, London, UK. WREN Laboratories, Branford, USA. Gastroenterological and Endoscopic Surgery, Yale University School of Medicine, New Haven, USA. Department of Gastroenterology/Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany. CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany
Adil Al-Nahhas - Department of Surgery and Cancer, Imperial College London, London, UK. Department of Nuclear Medicine, University College London Hospitals, London, UK. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. Department of Imaging and Nuclear Medicine, Imperial College London, London, UK. WREN Laboratories, Branford, USA. Gastroenterological and Endoscopic Surgery, Yale University School of Medicine, New Haven, USA. Department of Gastroenterology/Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany. CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany
Ali Alsafi - Department of Surgery and Cancer, Imperial College London, London, UK. Department of Nuclear Medicine, University College London Hospitals, London, UK. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. Department of Imaging and Nuclear Medicine, Imperial College London, London, UK. WREN Laboratories, Branford, USA. Gastroenterological and Endoscopic Surgery, Yale University School of Medicine, New Haven, USA. Department of Gastroenterology/Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany. CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany
Mark Kidd - Department of Surgery and Cancer, Imperial College London, London, UK. Department of Nuclear Medicine, University College London Hospitals, London, UK. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. Department of Imaging and Nuclear Medicine, Imperial College London, London, UK. WREN Laboratories, Branford, USA. Gastroenterological and Endoscopic Surgery, Yale University School of Medicine, New Haven, USA. Department of Gastroenterology/Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany. CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany
Irvin M. Modlin - Department of Surgery and Cancer, Imperial College London, London, UK. Department of Nuclear Medicine, University College London Hospitals, London, UK. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. Department of Imaging and Nuclear Medicine, Imperial College London, London, UK. WREN Laboratories, Branford, USA. Gastroenterological and Endoscopic Surgery, Yale University School of Medicine, New Haven, USA. Department of Gastroenterology/Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany. CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany
Dieter Hoersch - Department of Surgery and Cancer, Imperial College London, London, UK. Department of Nuclear Medicine, University College London Hospitals, London, UK. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. Department of Imaging and Nuclear Medicine, Imperial College London, London, UK. WREN Laboratories, Branford, USA. Gastroenterological and Endoscopic Surgery, Yale University School of Medicine, New Haven, USA. Department of Gastroenterology/Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany. CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany
Richard P. Baum - Department of Surgery and Cancer, Imperial College London, London, UK. Department of Nuclear Medicine, University College London Hospitals, London, UK. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. Department of Imaging and Nuclear Medicine, Imperial College London, London, UK. WREN Laboratories, Branford, USA. Gastroenterological and Endoscopic Surgery, Yale University School of Medicine, New Haven, USA. Department of Gastroenterology/Endocrinology, Zentralklinik Bad Berka, Bad Berka, Germany. CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany
Publication Details: International journal of medical sciences, Vol.18(10), pp.2166-2175
Publisher: Ivyspring International Publisher
Publication Date: 01/01/2021
Identifiers: 99828459502346; WOS:000648865600009
Academic Unit: School of Biosciences
Language: English
Resource Type: Journal article

A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms

Abstract

Files and links (1)

Metrics

Details

Usage Policy